The collection of data has become a
formality within pharmaceutical manufacturing.
Its real potential lies in analysis
combined with the knowledge to answer
complex questions. This kind of analysis is
often referred to as “Big Data.”
Big Data creates new possibilities for
the pharmaceutical and biotechnology
industry to drive operational and business
performance to higher levels. A handful
of pharmaceutical and biopharmaceutical
companies are seeing success with Big Data,
leveraging this analysis for more thorough
decision making and process optimization.
But taking advantage of Big Data requires
new strategies, processes, mindsets and
skills. It is easy to sit back and bemoan the
lack of solutions when it comes to new
technologies, like Big Data, in the industry.
Many others are in the same situation.
One way to get out of that bubble is to
make time for the 2017 PDA Annual
Meeting. On the last day of the conference,
Michele D’Alessandro, Vice
President & Chief Information Officer,
Manufacturing IT, Merck & Company,
Inc., and Adam Fermier, PhD, Scientific
Director, PDMS, Janssen Pharmaceuticals
R&D, will speak about their companies’
experiences with Big Data in the plenary
session, “Application of Big Data
for Manufacturing Process Design and
Other sessions at the meeting will look at
analytical sciences and process monitoring,
delivery system design, future facility
design, real-time release testing, immunotherapies,
manufacturing and logistics
for personalized medicines, analytical
sciences and quality control strategies,
development in patient-centered precision
medicine, next generation manufacturing
If you are new to the pharmaceutical and
biotechnology industry, or an experienced
professional interested in Big Data and
other new ideas, the 2017 PDA Annual
Meeting is an excellent opportunity to create,
improve and expand your networking
among new and long-standing colleagues.
For more information about the 2017 PDA Annual Meeting, and subsequent PDA Education courses, click here.